Home » Stocks » KZIA

Kazia Therapeutics Limited (KZIA)

Stock Price: $10.05 USD -0.15 (-1.47%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $10.29 +0.24 (2.39%) May 7, 4:10 PM
Market Cap 132.75M
Revenue (ttm) 731,724
Net Income (ttm) -8.60M
Shares Out 12.66M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $10.05
Previous Close $10.20
Change ($) -0.15
Change (%) -1.47%
Day's Open 10.33
Day's Range 9.80 - 10.36
Day's Volume 54,513
52-Week Range 2.50 - 15.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey ac...

3 days ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it  "a vastly stronger and more substantial business", according t...

1 week ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial gro...

1 week ago - Proactive Investors

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m...

2 weeks ago - Accesswire

Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company's in-licensing of EVT...

2 weeks ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European d...

2 weeks ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) is in a trading halt pending an announcement in regard to a potential in-licensing transaction. In its application to the ASX for the halt, Kazia...

3 weeks ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has secured an increased price target from A$2.25 to A$2.60 a share by Corporate Connect analyst Marc Sinatra on the back of two recent licensing...

3 weeks ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) will share new data from its ongoing phase II study of paxalisib in glioblastoma in a poster presentation at the prestigious American Association...

4 weeks ago - Proactive Investors

LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$11...

1 month ago - Accesswire

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (HKSE:2096) to develop and commercialise Kazia's investigational new...

1 month ago - Proactive Investors

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazia's investigational new drug, paxalisib, in Greater Ch...

1 month ago - Benzinga

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has been granted a trading halt by the ASX pending the release of an announcement regarding a regional licensing transaction. The halt will be in...

1 month ago - Proactive Investors

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) chief executive officer and MD James Garner has highlighted the company's progress over the course of the year to date in its March newsletter,...

1 month ago - Proactive Investors

Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cance...

Other stocks mentioned: OASM
2 months ago - Benzinga

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (STO:OASM) (OTCMKTS:OASMY) for Cantrixil (TRX-E-002-1), a cl...

Other stocks mentioned: OASM
2 months ago - Proactive Investors

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) made substantial progress and achieved key milestones in the half-year ending December 31, 2020, ending the period with a cash balance of A$19.4 ...

2 months ago - Proactive Investors

Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.

9 months ago - InvestorPlace

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 6, 1999
Stock Exchange
NASDAQ
Ticker Symbol
KZIA
Full Company Profile

Financial Performance

In 2020, KZIA's revenue was 1.06 million, a decrease of -32.20% compared to the previous year's 1.57 million. Losses were -12.47 million, 21.4% more than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for KZIA stock is "Buy" and the 12-month stock price forecast is 17.01.

Price Target
$17.01
Analyst Consensus: Buy